New anticancer immunotherapies

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2439-2454

  Franks, Hester A ^a   Wang, Qunwei ^a   Patel, Poulam M ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Adoptive T cell therapies protein vaccines; Cancer; Dendritic cell therapy; Immunotherapy; Ipilimumab; Oncolytic virus vaccines; Review; Sipulencel T; Vaccines

Indexed keywords

AMP 224; ANTINEOPLASTIC AGENT; BMS 936559; CANCER VACCINE; CARBOPLATIN; CG 0070; CT 011; CYCLOPHOSPHAMIDE; DACARBAZINE; DENDRITIC CELL VACCINE; FLUDARABINE; GLYCOPROTEIN GP 100; IMP 321; INFLIXIMAB; IPILIMUMAB; JX 594; MELANOMA ANTIGEN 3; MK 3475; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; NIVOLUMAB; ONCOLYTIC VIRUS; PACLITAXEL; REOLYSIN; SIPULEUCEL T; TALIMOGENE LAHERPAREPVEC; TEMOZOLOMIDE; TICILIMUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ADOPTIVE TRANSFER; ADRENAL INSUFFICIENCY; ADVANCED CANCER; ANTIGEN PRESENTING CELL; BLADDER CANCER; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CD8+ T LYMPHOCYTE; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; COLITIS; COLON CANCER; COLORECTAL CANCER; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DIABETES MELLITUS; DIARRHEA; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; ENDOPHTHALMITIS; FATIGUE; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HERPES SIMPLEX VIRUS; HUMAN; HYPERBILIRUBINEMIA; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNE RESPONSE; IMMUNOREGULATION; KIDNEY CANCER; LIPOSOMAL DELIVERY; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; MONOTHERAPY; MYASTHENIA GRAVIS; NATURAL KILLER CELL; NAUSEA; NONMYELOABLATIVE CONDITIONING; ONCOLYTIC VIROTHERAPY; OVARY CANCER; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REOVIRUS; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SARCOIDOSIS; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TH2 CELL; TUMOR LYSIS SYNDROME; UPREGULATION; VIRUS REPLICATION; WHOLE BODY RADIATION;

ANIMALS; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84865694926     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Adotevi O, Pere H, Ravel P, Haicheur N, Badoual C, Merillon N, Medioni J, Peyrard S, Roncelin S, Verkarre V, Mejean A, Fridman WH, Oudard S and Tartour E: A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 33: 991-998, 2010.
2. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H and Honjo T: Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8: 765-772, 1996. (Pubitemid 26148299)
3. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE and Rosenberg SA: Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114: 1537-1544, 2009.
4. Banchereau J and Steinman RM: Dendritic cells and the control of immunity. Nature 392: 245-252, 1998. (Pubitemid 28155090)
5. Benson DM, Jr., Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, Byrd JC and Caligiuri MA: The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116: 2286-2294, 2010.
6. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, Koren-Michowitz M, Shimoni A and Nagler A: Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 14: 3044-3051, 2008.
7. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A and Schachter J: Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 16: 2646-2655, 2010.
8. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A and Wigginton JM: Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. N Engl J Med 2012.
9. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R, Pelusio A, Le Boeuf F, Burns J, Evgin L, De Silva N, Cvancic S, Robertson T, Je JE, Lee YS, Parato K, Diallo JS, Fenster A, Daneshmand M, Bell JC and Kirn DH: Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477: 99-102, 2011.
10. Brentjens R, Yeh R, Bernal Y, Riviere I and Sadelain M: Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 18: 666-668, 2010.
11. Brignone C, Escudier B, Grygar C, Marcu M and Triebel F: A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res 15: 6225-6231, 2009.
12. Brignone C, Grygar C, Marcu M, Schakel K and Triebel F: A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. J Immunol 179: 4202-4211, 2007.
13. Brignone C, Gutierrez M, Mefti F, Brain E, Jarcau R, Cvitkovic F, Bousetta N, Medioni J, Gligorov J, Grygar C, Marcu M and Triebel F: First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 8: 71, 2010.
14. Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG and Golstein P: A new member of the immunoglobulin superfamily - CTLA-4. Nature 328: 267-270, 1987. (Pubitemid 17108278)
15. Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, Padley DJ, Peshwa MV, Pitot HC, Richardson RL, Smits BJ, Sopapan P, Strang G, Valone FH and Vuk-Pavlovic S: Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 6: 2175-2182, 2000. (Pubitemid 30399182)
16. Coffey MC, Strong JE, Forsyth PA and Lee PW: Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332-1334, 1998. (Pubitemid 28524498)
17. Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, Vile R, Melcher A, Coffey MC, Mettinger KL, Nuovo G, Cohn DE, Phelps M, Harrington KJ and Pandha HS: REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res 16: 5564-5572, 2010.
18. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E and Chen L: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793-800, 2002.
19. Donnelly OG, Errington-Mais F, Prestwich R, Harrington K, Pandha H, Vile R and Melcher AA: Recent Clinical Experience With Oncolytic Viruses. Curr Pharm Biotechnol 2011.
20. Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE, Restifo NP, Wunderlich JR, Prieto PA, Hong JJ, Langan RC, Zlott DA, Morton KE, White DE, Laurencot CM and Rosenberg SA: CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 16: 6122-6131, 2010.
21. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A and Rosenberg SA: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357, 2005. (Pubitemid 46218728)
22. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE and Rosenberg SA: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26: 5233-5239, 2008.
23. Errington F, Steele L, Prestwich R, Harrington KJ, Pandha HS, Vidal L, de Bono J, Selby P, Coffey M, Vile R and Melcher A: Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 180: 6018-6026, 2008.
24. Eshhar Z, Waks T, Gross G and Schindler DG: Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and Tcell receptors. Proc Natl Acad Sci USA 90: 720-724, 1993. (Pubitemid 23028937)
25. Figlin RA, Nicolette CA, Amin A, Dudek A, Logan T, Lance RS, Holzbeierlein JM, Pal SK, Master VA, DeBenedette M, Tcherepanova IY, Jain R, Williams WL, Miesowicz F and Monesmith T: Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib. Journal of Clinical Oncology 29, 2011.
26. Friedlander TW: Updated results of a phase 1/2 trial of intravesical CG0070 in patients with superficial bladder cancer after BCG failure. Genitourinary cancers symposium Abstract 2712012.
27. Gollamudi R, Ghalib MH, Desai KK, Chaudhary I, Wong B, Einstein M, Coffey M, Gill GM, Mettinger K, Mariadason JM, Mani S and Goel S: Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs 28: 641-649, 2010.
28. Green DR, Ferguson T, Zitvogel L and Kroemer G: Immunogenic and tolerogenic cell death. Nat Rev Immunol 9: 353-363, 2009.
29. Greene JL, Leytze GM, Emswiler J, Peach R, Bajorath J, Cosand W and Linsley PS: Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J Biol Chem 271: 26762-26771, 1996. (Pubitemid 26359085)
30. Hannani D, Sistigu A, Kepp O, Galluzzi L, Kroemer G and Zitvogel L: Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. Cancer J 17: 351-358, 2011.
31. Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, Beirne D, Prestwich R, Newbold K, Ahmed M, Thway K, Nutting CM, Coffey M, Harris D, Vile RG, Pandha HS, Debono JS and Melcher AA: Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res 16: 3067-3077, 2010.
32. Hashiro G, Loh PC and Yau JT: The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 54: 307-315, 1977. (Pubitemid 8167247)
33. Heinemann L, Simpson GR, Boxall A, Kottke T, Relph KL, Vile R, Melcher A, Prestwich R, Harrington KJ, Morgan R and Pandha HS: Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer 11: 221, 2011.
34. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N and Frohlich MW: Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115: 3670-3679, 2009.
35. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC and Dranoff G: Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105: 3005-3010, 2008. (Pubitemid 351723658)
36. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP and Dranoff G: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100: 4712-4717, 2003. (Pubitemid 36457795)
37. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A and Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723, 2010.
38. Hong DS, Vence L, Falchook G, Radvanyi LG, Liu C, Goodman V, Legos JJ, Blackman S, Scarmadio A, Kurzrock R, Lizee G and Hwu P: BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency. Clin Cancer Res 18: 2326-2335, 2012 .
39. Huang J, Kerstann KW, Ahmadzadeh M, Li YF, El-Gamil M, Rosenberg SA and Robbins PF: Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. J Immunol 176: 7726-7735, 2006. (Pubitemid 43849073)
40. Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA and Robbins PF: Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 28: 258-267, 2005. (Pubitemid 40593992)
41. Ilett EJ, Barcena M, Errington-Mais F, Griffin S, Harrington KJ, Pandha HS, Coffey M, Selby PJ, Limpens RW, Mommaas M, Hoeben RC, Vile RG and Melcher AA: Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin Cancer Res 17: 2767-2776, 2011.
42. Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M, Siemers NO, Jackson JR and Shahabi V: An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2011.
43. John F Thompson MS, Thomas Jouary, Eugeny Levchenko, Bernard Mark Smithers, Laurent Mortier, Jean Jacques Grob, Uwe Trefzer, Ralf Gutzmer, Corinne Jamoul, Olivier Peeters, Brigitte Dreno, John M. Kirkwood: MAGE-A3 expression in patients screened for the DERMA trial: A phase III trial testing MAGE-A3 immunotherapeutic in the adjuvant setting for stage IIIB-C-Tx melanoma. J Clin Oncol 302012.
44. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, VanWaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM and Rosenberg SA: Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114: 535-546, 2009.
45. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW and Schellhammer PF: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422, 2010.
46. Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, Coffey M, Thompson B, Mettinger K, Vile RG, Pandha HS, Hall GD, Melcher AA, Chester J and Harrington KJ: Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies. Clin Cancer Res 18: 2080-2089, 2012.
47. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS and Kim-Schulze S: Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 17: 718-730, 2010.
48. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA and Hwu P: A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12: 6106-6115, 2006. (Pubitemid 44703776)
49. Kirkwood JM, Dreno B, Hauschild A, Schadendorf D, Testori A, Hersey P, Jamoul C, Peeters O and Therasse P: DERMA phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in patients with MAGE-A3-positive resected stage III melanoma. J Clin Oncol 29: suppl abstr TPS232 2011.
50. Kirn DH, Wang Y, Le Boeuf F, Bell J and Thorne SH: Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med 4: e353, 2007.
51. Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ, June CH, Rosenberg S, Sadelain M and Heslop HE: CARs on track in the clinic. Mol Ther 19: 432-438, 2011.
52. Kruit W, Susiu S, Dreno B, Chiarion-Sileni V, Mortier L, Robert C, Maio M, Lehmann F, Brichard VG, Spatz A, Eggermont AM and Keilholz U: Active immunization toward the MAGE-A3 antigen in patients with metastatic melanoma: Four-year follow-up results from a randomized phase II study (EORTC16032-18031). Journal of Clinical Oncology 29, 2011.
53. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G and Oosterwijk E: Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24: e20-22, 2006.
54. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C and Sharma P: CTLA-4 blockade increases IFNgamma-producing CD4+ ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA 105: 14987-14992, 2008.
55. Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, McGrath Y, Thomas SK, Thornton M, Bullock P, Love CA and Coffin RS: ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 10: 292-303, 2003. (Pubitemid 36305598)
56. Liu TC, Hwang T, Park BH, Bell J and Kirn DH: The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 16: 1637-1642, 2008.
57. Louahed J, Gruselle O, Gaulis S, Coche T, Eggermont AM, Kruit W, Dreno B, Chiarion Sileni V, Lehmann F and Brichard VG: Expression of defined genes identified by pretreatment tumor profiling: Association with clinical responses to the GSK MAGEA3 immunotherapeutic in metastatic melanoma patients (EORTC 16032-18031). J Clin Oncol 26: suppl abstr 9045, 2008.
58. Luker KE, Hutchens M, Schultz T, Pekosz A and Luker GD: Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread. Virology 341: 284-300, 2005. (Pubitemid 41417785)
59. Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ and Kalinski P: alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Research 64: 5934-5937, 2004. (Pubitemid 39129387)
60. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA and Rosenberg SA: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129, 2006. (Pubitemid 44547756)
61. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM and Rosenberg SA: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18: 843-851, 2010.
62. Nesselhut J, Marx D, Lorenzen D, Cillien N, Goebel W, Chang RY, Brockmann W, Peters JH, Nesselhut K, Fändrich F and Nesselhut T: Improvement of dendritic cell therapy in glioblastoma multiforme WHO 4 by Newcastle disease virus. Journal of Clinical Oncology 29, 2011.
63. Neyns B, Wilgenhof S, Van Nuffel AMT, Benteyn D, Heirman C, Van Riet I, Bonehill A, Corthals J and Thielemans K: A phase I clinical trial on the combined intravenous (IV) and intradermal (ID) administration of autologous TriMix-DC cellular therapy in patients with pretreated melanoma (TriMixIDIV). Journal of Clinical Oncology 29, 2011.
64. Nishimura H, Nose M, Hiai H, Minato N and Honjo T: Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11: 141-151, 1999. (Pubitemid 29428807)
65. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N and Honjo T: Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291: 319-322, 2001. (Pubitemid 32096320)
66. Okada H, Kalinski P, Mintz AH, Engh JA, Butterfield LH, Hamilton RH, Potter DM, Salazar AM and Lieberman FS: Phase I/II vaccine study targeting novel HLA-A2-restricted CTL epitopes in combination with poly-ICLC in patients with recurrent malignant glioma. Journal of Clinical Oncology 29, 2011.
67. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, Oh SY, Han SY, Yoon JH, Hong SH, Moon A, Speth K, Park C, Ahn YJ, Daneshmand M, Rhee BG, Pinedo HM, Bell JC and Kirn DH: Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 9: 533-542, 2008.
68. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, Robbins PF, Laurencot CM and Rosenberg SA: T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19: 620-626, 2011.
69. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB and Riley JL: CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 25: 9543-9553, 2005. (Pubitemid 41507854)
70. Powell DJ, Jr., Dudley ME, Robbins PF and Rosenberg SA: Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105: 241-250, 2005. (Pubitemid 40053089)
71. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE and Brenner MK: Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14: 1264-1270, 2008.
72. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, Baker J, Jeffery LE, Kaur S, Briggs Z, Hou TZ, Futter CE, Anderson G, Walker LS and Sansom DM: Transendocytosis of CD80 and CD86: a molecular basis for the cellextrinsic function of CTLA-4. Science 332: 600-603, 2011.
73. Ribas A: Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin Oncol 37: 450-454, 2010.
74. Riley JL, Mao M, Kobayashi S, Biery M, Burchard J, Cavet G, Gregson BP, June CH and Linsley PS: Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS and CTLA-4 receptors. Proc Natl Acad Sci USA 99: 11790-11795, 2002. (Pubitemid 34994477)
75. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, Huang J, Powell DJ Jr. and Rosenberg SA: Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 173: 7125-7130, 2004. (Pubitemid 39628146)
76. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C and Rosenberg SA: Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29: 917-924, 2011.
77. Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr., Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A and Wolchok JD: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526, 2011.
78. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA et al: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319: 1676-1680, 1988. (Pubitemid 19015247)
79. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH and White DE: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86: 1159-1166, 1994. (Pubitemid 24249302)
80. Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, Wu Z, Joyce R, Levine JD, Dombagoda D, Yuan YE, Francoeur K, Fitzgerald D, Richardson P, Weller E, Anderson K, Kufe D, Munshi N and Avigan D: Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 117: 393-402, 2011.
81. Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, Wei B, Hogg N, Garside P and Rudd CE: Reversal of the TCR stop signal by CTLA-4. Science 313: 1972-1975, 2006. (Pubitemid 44498006)
82. Schwartzentruber DJ, Kirkwood JM, Guarino MJ, Richards JM, Hamid O, O'Day S, Nemunaitis JJ, Talmadge JE, Chada S, Menander KB, Shafer-Weaver K, Senesac JH, Thornton MO, Lewis JJ and Herberman RB: Immunotherapy of advanced melanoma by intratumoral injections of autologous, purified dendritic cells transduced with gene construct of interleukin-12, with dose-dependent expression under the control of an oral activator ligand. Journal of Clinical Oncology 29, 2011.
83. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, Goldsweig H, Marshall T, Love C, Coffin R and Nemunaitis JJ: Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27: 5763-5771, 2009.
84. Sfanos KS, Bruno TC, Meeker AK, De Marzo AM, Isaacs WB and Drake CG: Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate 69: 1694-1703, 2009.
85. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ and Schreiber RD: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111, 2001. (Pubitemid 32391043)
86. Shapira-Frommer R, Besser M, Kuchuk I, Nave R, Zippel D, Treves A, Nagler A, Apter S, Shimoni A, Yerushalmi R, Ben-Ami E, Ben-Nun A, Markel G, Itzhaki O, Catane R and Schachter J: Adoptive transfer of short-term cultured tumor-infiltrating lymphocytes (young TIL) in metastatic melanoma patients. Journal of Clinical Oncology 29, 2011.
87. Sheikh NA and Jones LA: CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol Immunother 57: 1381-1390, 2008.
88. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV and Valone FH: Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18: 3894-3903, 2000.
89. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA and Hershberg RM: Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24: 3089-3094, 2006. (Pubitemid 46638945)
90. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I and Allison JP: A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13: 1810-1815, 2007. (Pubitemid 46952950)
91. Strong JE, Coffey MC, Tang D, Sabinin P and Lee PW: The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 17: 3351-3362, 1998. (Pubitemid 28279509)
92. Strong JE, Tang D and Lee PW: Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency. Virology 197: 405-411, 1993.
93. Thirukkumaran CM, Nodwell MJ, Hirasawa K, Shi ZQ, Diaz R, Luider J, Johnston RN, Forsyth PA, Magliocco AM, Lee P, Nishikawa S, Donnelly B, Coffey M, Trpkov K, Fonseca K, Spurrell J and Morris DG: Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer research 70: 2435-2444, 2010.
94. Thorne SH, Hwang TH, O'Gorman WE, Bartlett DL, Sei S, Kanji F, Brown C, Werier J, Cho JH, Lee DE, Wang Y, Bell J and Kirn DH: Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 117: 3350-3358, 2007. (Pubitemid 350096991)
95. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, Qian X, James SE, Raubitschek A, Forman SJ, Gopal AK, Pagel JM, Lindgren CG, Greenberg PD, Riddell SR and Press OW: Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112: 2261-2271, 2008.
96. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA and Sharpe AH: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-547, 1995.
97. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM and Sznol M: Safety, Activity and Immune Correlates of Anti-PD-1 Antibody in Cancer. N Engl J Med 2012.
98. Turtle CJ and Riddell SR: Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy. Curr Opin Immunol 23: 299-305, 2011.
99. van der Merwe PA, Bodian DL, Daenke S, Linsley P and Davis SJ: CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 185: 393-403, 1997. (Pubitemid 27078358)
100. Vansteenkiste JF, Zielinski M, Dahabreh IJ, Linder A, Lehmann F, Gruselle O, Therasse P, Louahed J and Brichard VG: Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 26: suppl abstr 7501, 2008.
101. Vansteenkiste J, Zielinski M, Linder A, Dahabre J, Esteban E, Malinowski W, Jassem J, Passlick B, Lehmann F and Brichard VG: Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 25, 2007.
102. Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, Melcher A, Coffey M, Harrington KJ and DeBono JS: A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 14: 7127-7137, 2008.
103. Vieira PL, de Jong EC, Wierenga EA, Kapsenberg ML and Kalinski P: Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol 164: 4507-4512, 2000. (Pubitemid 30238046)
104. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H and Mak TW: Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270: 985-988, 1995.
105. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, Kefford RF, Hersey P and Scolyer RA: Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 18: 1386-1394, 2012.
106. Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, Panageas KS, Ritter G, Sznol M, Halaban R, Jungbluth AA, Allison JP, Old LJ, Wolchok JD and Gnjatic S: Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA 108: 16723-16728, 2011.
107. Zhou J, Dudley ME, Rosenberg SA and Robbins PF: Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother 28: 53-62, 2005. (Pubitemid 40075938)
108. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA and Robbins PF: Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 175: 7046-7052, 2005. (Pubitemid 41598952)